Post-marketing study to assess serotype-specific effectiveness of Reassortant Rotavirus Vaccine, Live, Oral, Pentavalent (Vero Cell) (ROTATEQ®) in China (V260-077)

03/09/2020
05/09/2025
EU PAS number:
EUPAS36666
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

V260-077-00-v2-China PMC-Prot_Final Redaction Part 1 Pages 1-28

English (631.4 KB - PDF) View document
Updated protocol

V260-077-V6.0-final-redaction.pdf

First published: 13/12/2024
English (700.3 KB - PDF) View document
Study results
Study report
Other information
Study, other information

V260-077-00-v2-China PMC-Prot_Final Redaction Part 2 Pages 29-51_1

English (349.89 KB - PDF) View document

V260-077-00-v4_protocol_final-redaction

English (1.56 MB - PDF) View document

V260-077-00-v5-Protocol_final-redaction.pdf

English (395.08 KB - PDF) View document